Allergan breast implant lawsuits is all about Allergan breast implants causing Breast Implant-Associated Anaplastic Large Cell Lymphoma. Gavin S. Herbert, a pharmacist, founded Allergan Pharmaceuticals in 1948. Initially established as an American multinational pharmaceutical company, Allergan, Inc. focused on medical aesthetics, neurosciences, medical dermatology, urologics, breast augmentation, and ophthalmology.

The outer shell of Allergan breast implants is composed of silicone elastomer, a kind of silicone with elastic qualities akin to those of rubber. Seawater solution, sterile saline, or silicone gel can be used to fill the shells.

In comparison to other textured implants, the Food and Drug Administration announced on July 24, 2019, that it had found evidence connecting Allergan BIOCELL textured breast implants to a higher incidence of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Approximately 85% of BIA-ALCL cases, according to the FDA, have involved recipients of Allergan's BIOCELL® textured implants.

A rare kind of non-Hodgkin's lymphoma that is different from breast cancer is called BIA-ALCL. Since the early 1990s, attempts have been made to gain a deeper understanding of the condition's causes, symptoms, and effects.

The Allergan BIOCELL textured breast implant products covered in the recall are as follows.

  • Natrelle Saline-Filled breast implants
  • Natrelle Silicone-Filled breast implants
  • Natrelle Inspira Silicone-Filled breast implants
  • Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled breast implants
  • Natrelle 133 Plus Tissue Expander
  • Natrelle 133 Tissue Expander with Suture Tabs

Several months after the company's recall, federal lawsuits against Allergan's Natrelle BIOCELL Textured Breast Implants emerged. In December 2019, the U.S. Judicial Panel on Multidistrict Litigation consolidated all federal cases into a New Jersey MDL class action.

Allergan BIOCELL Textured Breast Implant Products Liability Litigation, No. 2:19-md-02921, MDL No. 2921 (D.N.J.) is the multi-district litigation. The MDL, which is pending in the US District Court for the District of New Jersey, brings claims on behalf of American women who were harmed by Allergan's Biocell® Textured Breast Implants for personal injuries, economic damages, and medical monitoring.